New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy

UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, highlights the results of a sub-analysis from the first and largest real-world patient cohort review of JELMYTO for pyelocalyceal solution presented at the American Urological Association Meeting 2024 in San Antonio, TX.